Q4BS GmbH
Q4BS
Intended future excellence in Life science Healthcare Human-centric decision-making and agentic AI Desicioning (aAID).
ID: 651680293171-86
Lobbying Activity
Response to EU Start-up and Scale-up Strategy
15 Mar 2025
First: Capital and IP complexity Q4BS agrees to Capital and Intellectual Property. Innovative startups encounter significant difficulties in securing investment capital because their ideas, particularly in early stages, cannot easily be patented or fully protected as intellectual property. This inability to clearly establish IP rights prior to product development difficults investment, as the risk of imitation or loss of competitive advantage is higher. Consequently, promising innovations fail to attract privat funding until they have already matured into prototyped, protectable products, which depends on high investments by early-startups themself based on mostly limited capital. Second: Regulatory complexity Q4BS agrees to Early-stage startups face challenges in translating their ideas into viable commercial ventures, largely due to the complexity and variability of regulatory requirements involved in establishing new businesses. Regulatory hurdles differ from country to country within the EU, creating inner-European unequal opportunities for cross-border cooperation and innovation. This fragmented regulatory environment often hinders collaborative ventures and places European startups in competitive disadvantage compared to those operating in more harmonized markets like US. Third: EU market complexity Q4BS agrees to Startups often find the EU market complex and challenging to navigate due to its fragmented nature and differing national market entry regulations. The diversity of legal frameworks and procedures across EU member states creates substantial barriers, making it difficult for startups to efficiently scale their operations. Moreover, complexities in accessing public procurement opportunities further hinder their growth and market expansion potential, limiting their ability to fully capitalize on the unified market's potential benefits. Forth: Talent search complexity Q4BS partially agrees by Early Start-ups are ideaed by talents therefore do not necessary face the complexity to finding the talents the same way as established enterprises due to higher flexibility and attractive thematic. But a complexity can be seen in various often entity owned decentralized matchmaking platforms for collaboration and a missing open-lab start-up matchmaking platform by EU reserach and innovation centers. Fifth: Commercial entity research collaboration Q4BS agrees to Commercially-driven or profit-oriented startups often face difficulties establishing their own research activities due to effort and less scientific acceptance, or collaborating effectively with national research institutions. Challenges arise primarily due to intellectual property (IP), patent-related issues, and less speed to marked academic mission of research institutions. Research institutions typically retain rights to IP generated through joint research projects, which limits the startup's ability to fully exploit their market driven research results commercially. As a result, collaboration becomes complicated to contract and licensing, potentially hindering the startup ability to innovate and bring new products or services to market on demand. Q4BS seen actions to address these hurdles: Simplification, Navigation, Orchestration The previously outlined challenges faced by startups can be significantly mitigated through strategic actions involving simplification, navigation, and orchestration. Simplification aims at reducing regulatory and eraly stage patents, enabling startups to efficiently establish and operate open across diverse markets. Navigation refers to the guidance and support systems that help startups identify and understand matchmaking, intellectual property, and fund raising. Orchestration involves B2X collaboration and partnerships between startups, research institutions, investors, and regulatory bodies to ensure simple commercialization pathways and access to resources and opportunities.
Read full response